The HSE has received an application for the reimbursement of dapagliflozin under the GMS and community drugs schemes.
The application is being considered in line with the procedures and timescales agreed last year by the Department of Health and the HSE with the Irish Pharmaceutical Healthcare Association (IPHA) for the assessment of new medicines.
The product has completed the rapid review process and a health technology assessment is ongoing. It would not be appropriate at this time to make any further comment in relation to the outcome of the process.